growth factor 21 (FGF21) is a hormone that is expressed predominantly in the liver, but also in other metabolically active tissues such as pancreas, skeletal muscle and adipose tissue. In animals, FGF21 lowers blood glucose levels and inhibits glucagon secretion. In humans, circulating FGF21 levels are increased in insulin-resistant mor-
bidities such as obesity and type 2 diabetes mellitus (T2DM). An elevated FGF21
level is also an independent predictor of T2DM. GDM and T2DM are proposed to have similar underlying pathophysiologies, raising the question of whether a similar relationship exists between FGF21 and GDM as it does with T2DM. There are a limited number of studies investigating FGF21 levels in patients with GDM. Moreover, recent clinical trials investigating the therapeutic potential of FGF21 have highlighted a major gap in our understanding of the biology of FGF21. This review evaluates what is currently known about FGF21 and GDM and highlights important gaps that warrant further research.
K E Y W O R D S
biomarkers, diabetes mellitus, fibroblast growth factor 21, gestational diabetes, insulin resistance, pregnancy, risk factors with a significant increase in the risk of developing long-term adverse health problems such as obesity, type 2 diabetes mellitus (T2DM) and cardiovascular disease in both the mother and the child. 2, 7, 10, 11 Fibroblast growth factor 21 (FGF21) was first identified in 2000. 12 It is mainly expressed in the liver but also in other metabolically active tissues such as pancreas, skeletal muscle, adipose tissue and placenta. [13] [14] [15] FGF21 has emerged as an important regulator of energy metabolism that has beneficial effects on glucose and lipid homoeostasis. 13 In animal studies, FGF21 lowered blood glucose levels and inhibited glucagon secretion. 16 , 17 Kharitonenkov et al 13, 18 established that the ability of FGF21 to improve glycaemic control may be due to an insulin-independent increase in glucose uptake by adipocytes by the glucose transporter, GLUT1.
In humans, FGF21 levels are increased in insulin-resistant morbidities such as obesity and T2DM. 19 Furthermore, in epidemiological studies, a high plasma FGF21 level is an independent predictor of T2DM. 20 Although the underlying mechanisms for development of GDM remain unclear, the pathophysiology of GDM and T2DM is proposed to be similar. Both involve insulin resistance and insulin insufficiency due to impaired pancreatic beta cell function. 21, 22 This leads to the question of whether there is a relationship between FGF21 levels and GDM, as is the case with FGF21 levels and T2DM.
There are a limited number of studies investigating circulating levels of FGF21 in patients with GDM compared to those without. 15, 21, [23] [24] [25] [26] [27] [28] This review aims to synthesize data from original research on FGF21 levels in patients with GDM in order to guide future research directions and to explore the therapeutic potential of FGF21 in GDM.
| PHYS I OLOG I C AL FUN C TI ON OF FG F21
FGF21 is part of the endocrine FGF subfamily that consists of 3 members, FGF19, 21 and 23 all with hormone like actions. 29 FGF21
exerts its actions through acting on fibroblast growth factor receptors (FGFR) 1-4, although most actions are mediated through FGFR1. 30 The functional FGF21 receptor complex consists of FGFR and its co-receptor β klotho (KLB), with both being essential for FGF21 signalling (Figure 1 ). 31 The binding of FGF21 to the receptor complex results in monomeric dimerization of FGFR and autophosphorylation of FGFR tyrosine residues. This leads to the phosphorylation of tyrosine residues in the docking protein FGFR substrate 2 (FRS2). Phosphorylated FRS2 then forms a complex with the adaptor protein, growth factor receptor-bound protein 2 (Grb2) and the Ras guanine nucleotide exchange factor, Son of Sevenless (Sos). This results in the activation of the Akt and extracellular signal-regulated kinase (ERK) signalling pathways. [32] [33] [34] FGF21 administration improves both hepatic and peripheral insulin sensitivity in mice maintained on a regular chow or high-fat diet.
This is achieved through reduction in hepatic lipid intermediates, including triglycerides and cytosolic and membrane diacylglycerol. 35 The reduced hepatic diacylglycerol content decreases protein kinase Cε activation and simultaneously increases insulin-stimulated Akt2 phosphorylation. 35 FGF21 may promote hepatic lipid clearance and insulin sensitivity through inhibition of growth hormone signalling in mouse liver. 36 FGF21 increases islet insulin content and glucosestimulated insulin secretion (GSIS) in diabetic db/db mouse islets. 37 Moreover, activation of ERK1/2 and Akt signalling pathways by FGF21 prevents palmitic acid and pro-inflammatory cytokines from reducing GSIS and promoting apoptosis in isolated islets and INS-1E cells. 37 FGF21 is expressed and secreted in skeletal muscle of humans 38 and rodents 39 where it acts as a myokine. Exposure to FGF21 increases basal and insulin-stimulated glucose uptake in human myotubes. It also increases insulin-stimulated glucose transport in isolated extensor digitorum longus muscle. 40 FGF21 increases insulin sensitivity in skeletal muscle in mice by reducing diacylglycerol levels and protein kinase Cθ activation and increasing glucose uptake and insulin-stimulated Akt2 phosphorylation. 35 As mentioned before FGF21 increases glucose uptake by adipocytes through GLUT1, 13, 18 and treatments with FGF21 increases insulin-mediated glucose up- 
| CIRCUL ATING FG F21 LE VEL S
In the literature, circulating FGF21 levels are usually highly skewed and are often determined using enzyme-linked immunochemistry assays (ELISA). FGF21 levels are reasonably stable and do not vary significantly after repetitive freeze-thaw cycles. 47, 48 Some studies have shown that circulating FGF21 levels exhibit a characteristic diurnal rhythm in humans, with a major rise occurring between midnight and early morning. 49, 50 This rhythm of FGF21 release aligns with the hypothesis that FGF21 is an important metabolic regulator that integrates with the circadian rhythm of energy homoeostasis in humans. 49 FGF21 levels correlate with different cardiometabolic conditions, and higher FGF21 levels are associated with cardiovascular disease risk factors such as chronic inflammation, obesity, hypertriglyceridaemia and elevated liver enzyme levels. 51, 52 Several studies have revealed that serum FGF21 levels are independently associated with metabolic disturbances, and that high levels of FGF21 predict impaired glucose metabolism. 53 
| FG F21 LE VEL S IN PATIENTS WITH G DM
To identify the relevant literature, the electronic databases PubMed and Medline (Ovid) were searched using the queries: "FGF21 AND Gestational Diabetes Mellitus" and "FGF21 AND Diabetes AND pregnancy". Only studies published in English were included in this review. Those published in abstract format only were excluded. A total of 13 studies on human GDM were identified from the database searches up to 1 September 2018. After manually reviewing
the full text of all articles, four studies were excluded as they had a different focus. This review discusses the remaining nine original research articles. Table 1 summarizes the major findings of these studies.
| Studies with a significant difference in circulating FGF21 between GDM and control patients
Of the nine studies, five reported a difference in circulating FGF21 levels between women with GDM and those with normal glycaemic control.
A study of 101 pregnant women of north-eastern Chinese ethnicity at the 28th week of gestation found significantly higher serum FGF21 levels among women with GDM than in controls matched for gestational age and weight (400 ± 128 ng/L vs 248 ± 107ng/L, P < 0.01). 25 A similar study of 90 pregnant women of Chinese ethnicity also revealed that serum FGF21 levels were higher in patients with GDM (median: 125 pg/mL; IQR 83-190) compared to controls (median 68 pg/mL; IQR 49-98 pg/mL; P < 0.001). 24 Based on previous studies on the role of FGF21 in different metabolic diseases with similar pathophysiological mechanisms to GDM, it can be speculated that this upregulation of FGF21 may be a compensatory mechanism for the underlying insulin resistance in order to increase whole-body
Mechanisms by which FGF21 improves glycaemic control in mouse and in vitro cell culture models. FGF21 increases fatty acid oxidation and improves insulin sensitivity whilst decreasing GH signalling and lipid content in the liver. In skeletal muscle, FGF21 improves insulin sensitivity and promotes glucose uptake whilst decreasing lipid content. FGF21 stimulates glucose uptake and thermogenesis in BAT whilst in WAT it attenuates lipolysis and increases glucose uptake and adiponectin secretion. These help to improve peripheral insulin sensitivity. In the pancreas, FGF21 enhances β cell survival and improves glucose-stimulated insulin secretion. glucose disposal. 54 The elevated FGF21 levels may also reflect FGF21 resistance, due to impaired interactions of FGF21 with its receptor and downregulation of downstream signalling pathways, which results supraphysiological concentrations of FGF21 being required to achieve a protective physiological function. 55 In fact, it is unclear how the impairment of the FGF21 signalling pathway, and hence FGF21 resistance, develops in GDM and other metabolic diseases.
The elevation of FGF21 levels in GDM is consistent with the findings of Tan et al 23 This possibility is consistent with a study of 157 subjects of European-Mediterranean descent in which maternal FGF21 plasma levels were higher in the GDM group compared to controls with normal glucose tolerance that were matched for age and prepregnancy BMI, whereas cord blood FGF21 levels were similar in both groups. 27 What is worth noting is that cord blood FGF21 levels were positively associated with child's BMI at 12 and 24 months of age in the normal glucose tolerance (NGT) group but not in the GDM group. This raises the possibility that, as FGF21 is able to cross blood-brain barrier and act on the central nervous system, FGF21 resistance may be initiated in offspring during intrauterine life. Furthermore, the lack of association between cord blood FGF21 levels and the BMI of the children in the GDM group indicates that a hyperglycaemic intrauterine environment could affect the impact of FGF21 on postnatal growth. However, further studies are needed to elucidate the basis of elevated FGF21 levels in GDM and whether FGF21 resistance exists in GDM. 55 On the contrary, a recent study by Xu C et al 57 involving 100 subjects reported that serum FGF21 levels were lower in patients with GDM compared to those in healthy individuals. However, in that study, the control group was not pregnant, which was a major limitation. Moreover, there were no details on maternal blood collection, and the reported FGF21 levels were lower than those found in other studies. Therefore, interpretation of this contradictory finding should be viewed with caution.
| Studies that failed to find a difference in circulating FGF21 levels
Despite the aforementioned positive findings on the relationship between FGF21 levels and patients with GDM, three studies failed to find a significant difference in FGF21 levels between patients with GDM and NGT.
In a study of 180 pregnant women between 24 and 28 weeks of gestation, no significant difference in plasma FGF21 levels was observed between GDM subjects and controls matched for age, BMI and gestational age. 21 Although FGF21 levels were determined by enzyme-linked immunosorbent assays using commercial kits from a different manufacturer, this is unlikely to explain the difference as the basic assay principles are the same. Moreover, another study of 38 subjects also showed no difference in serum FGF21 levels between GDM patients and controls matched for gestational age and BMI. 15 These results are consistent with those of Stein et al 26 who also found no difference between GDM patients and controls matched for gestational age and fasting insulin. Moreover, in a recent study of 45 subjects in whom FGF21 levels were measured at the time of elective caesarean section, maternal serum FGF21 levels were comparable between GDM patients and controls. 28 Together, all these studies showing comparable circulating FGF21 levels in pregnant women with and without GDM were not consistent with the beneficial effects of FGF21 on glucose metabolism found in animal studies. 13, 18 The main reason for these discrepant results may be that all of these studies were very small and the results may simply be a reflection of chance findings. Therefore, further studies with much larger sample sizes, and a multi-ethnic, longitudinal study design is warranted. Furthermore, all of the previous studies have the limitation of being cross-sectional, with FGF21 levels being measured at a single time point only.
| FGF21 in cord blood and placenta
The placenta is a highly metabolically active organ that secretes hormones and growth factors into the maternal and foetal circulation where they exert paracrine and endocrine effects. Expression of FGF21 in the placenta could influence placental metabolism, nutrient transfer and therefore foetal growth. FGF21 could also elicit its metabolic effects directly on the foetus.
In a study of 157 pregnant women with either GDM or NGT, FGF21 was present in foetal cord blood; however, no significant differences in concentration were observed between the groups. 27 By contrast, another study by Nitert et al 15 involving 38 women with GDM or normoglycaemia failed to detect FGF21 in cord blood of any of the babies, irrespective of the mother's glucose status. The discrepancy between these two findings is not clear, although Megia et al 27 suggested that it may be due to the different origins of the cord blood.
In the latter study, arterial and venous blood was collected, whilst in the first study only blood from the umbilical vein, which carries oxygen and nutrients to the foetus, was used. However, there is currently no report on FGF21 concentration gradients across different blood vessels. Nevertheless, higher FGF21 mRNA and protein levels were both detected in the placentae of women with GDM relative to normoglycaemic women in the study by Nitert et al 15 Furthermore, in the study by Li et al 25 , FGF21 levels were tracked until the 7th day post-partum by which time glucose levels in the GDM group had returned to normal, and FGF21 levels had decreased significantly in both the GDM and NGT patients. With reports of the placenta being an important organ for expression of FGF21, and potentially increased expression of FGF21 levels in GDM patients, it can be speculated that placental FGF21 may enter the maternal circulation in pregnant women with GDM thereby increasing circulating FGF21. 15, 25 Despite the positive findings from the study of Nitert et al, 15 data on FGF21 expression in the placenta are discordant. In a recent study by Wang et al, 28 no significant differences were found between GDM women and controls in regard to FGF21 mRNA and protein levels in the placenta. This difference could be partly explained by the different diagnostic criteria of GDM between the two studies, resulting in the fact that glycaemic levels of subjects in the Wang et al study were significantly higher than those in the Nitert et al study. Moreover, prepregnancy BMI was significantly higher in the Nitert et al study. The extent to which these factors contribute to the observed differences is questionable, but it highlights the need for further investigation before a definitive conclusion can be made about the role of FGF21 in the regulation of intrauterine foetal growth. Furthermore, in an earlier study by Tan et al, 23 secretion of FGF21 from placental explants into conditioned media was significantly lower for explants from GDM women compared to non-GDM controls. This finding, which is not consistent with the observations of Nitert et al, could potentially be explained by the fact that culturing placenta from GDM women in a normal media may reduce FGF21 expression and secretion.
Moreover, culturing tissue explants in a medium may not necessarily represent the in vivo picture. Taken together, the contradictory observations about placental FGF21 expression and secretion in GDM women highlight the need for further research.
| THER APEUTI C P OTENTIAL OF FG F21
As there are only a limited number of studies on the role of FGF21
in GDM, the potential beneficial effect of FGF21 in GDM is mainly extrapolated from studies on T2DM. It has been shown that systemic administration of FGF21 markedly reduces blood glucose and insulin levels in rodent and nonhuman primate models of T2DM. 18, 29 Studies in genetically modified mice and mice with diet-induced obesity (DIO) also show that FGF21 administration decreases hepatic triglyceride, plasma triglyceride and blood glucose levels and induces weight loss by increasing energy expenditure and reducing fat mass without affecting food intake. 29, 45 Systemic administration of FGF21 also has a profound effect on insulin sensitivity. 29 A single injection of recombinant FGF21 given to insulin-resistant rodents decreases blood glucose concentrations and improves glucose tolerance and insulin sensitivity in both leptin-deficient ob/ob mice and DIO mice. 58 Treatment of DIO mice with FGF21 for longer periods (3-6 weeks) also reverses hepatic steatosis, decreases hepatic glucose production, and increases insulin-stimulated glucose uptake in the heart, adipose tissue and skeletal muscle. 29, 45 These pharmacological actions, combined with its ability to decrease insulin resistance, makes FGF21 an attractive option for treatment of diabetes mellitus, and possibly GDM.
Given that metabolic benefits of FGF21 in preclinical models of obesity and T2DM are striking, there is compelling rationale for ongoing clinical development of FGF21 and FGF21 mimetics. 59 The FGF21 analog LY2405319 (LY) has been identified as a candidate for early-phase clinical development. In a 28 day randomized, placebocontrolled, proof of concept study of 178 subjects with obesity and T2DM, a statistically significant improvement in the lipid profile was observed after treatment with LY. 60 There was also a trend towards decreased fasting blood glucose levels with higher doses of LY. 
| CON CLUS ION
With the global prevalence of GDM increasing along with associated epidemics of obesity and T2DM, and hepatic and plasma triglyceride levels. 29, 45, 58 However the FGF21 mimetics LY and PF had no effect on glycaemic control despite improving lipid profiles in human clinical trials. 60, 62 This highlights a major gap in our understanding of the pharmacology and biology of FGF21. It also highlights the fact that preclinical studies in mice may not be a useful surrogate of FGF21 biology in humans.
Moreover, before FGF21 can be considered as a potential drug for treatment and prevention of GDM, more studies are needed to clarify the mechanisms by which FGF21 regulates glycaemic control in humans.
In summary, although understanding of FGF21 biology, and its role in T2DM, has increased in the past decade, its role in GDM is not well 
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